SectorPharmaceutical
Established Date11/12/2017
Listing Date18/05/2021
ExchangeNASDAQ Stock Exchange
Full-time Employees60
Fiscal Year Ends31/12
Security TypeCommon stock
Office addressBahnhofstrasse 20, CH-6300 Zug, Switzerland
Business
IntroductionOculis Holding AG was incorporated under the laws of Switzerland on December 11, 2017. The Company is a clinical-stage biopharmaceutical company headquartered in Switzerland with extensive expertise in therapies for the treatment of eye diseases and is involved in the development of innovative drug candidates with the potential to address many eye diseases. Their focus is on advancing therapeutic candidates to treat major ophthalmic diseases that lead to vision loss, blindness or reduced quality of life. Their clinical portfolio currently includes three therapeutic drug candidates: OCS-01, OCS-02 and OCS-05.
